scholarly journals Pathological Chemotherapy Response Score Predicts Survival in Patients with Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis of Individual Patient Data

2018 ◽  
Author(s):  
Paul Cohen ◽  
Aime Powell ◽  
Steffen Böhm ◽  
C. Blake Gilks ◽  
Colin J.R. Stewart ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Advanced Ovarian Cancer ◽  
Patient Data ◽  
Chemotherapy Response ◽  
Response Score

The design of a meta-analysis collecting individual patient data in advanced ovarian cancer

1990 ◽  
Vol 11 (4) ◽  
pp. 255
Author(s):  
Lesley Stewart ◽  
Mahesh Parmar ◽  
Chris Williams ◽  
David Guthrie
Keyword(s):  
Ovarian Cancer ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Advanced Ovarian Cancer ◽  
Patient Data

scholarly journals Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis

2019 ◽  
Vol 29 (8) ◽  
pp. 1285-1291 ◽  
Author(s):  
Satyam Kumar ◽  
Joanna Long ◽  
Sean Kehoe ◽  
Sudha Sundar ◽  
Carole Cummins
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Meta Analysis ◽  
Advanced Ovarian Cancer ◽  
Life Outcomes ◽  
Quality Of Life Outcomes ◽  
Extensive Surgery

BackgroundQuality of life after ovarian cancer treatment is an important goal for patients. Complex debulking surgeries and platinum based chemotherapy are often required but quality of life after surgery is rarely reported.ObjectivesTo describe quality of life outcomes after surgery for advanced ovarian cancer in a systematic review and meta-analysis.Search strategyMEDLINE, EMBASE, and CENTRAL through March 2019 with no language restrictions.Selection criteriaIncluded studies reported quality of life in women diagnosed with primary advanced ovarian cancer, fallopian tube carcinoma or primary peritoneal cancer undergoing cytoreduction surgery.Data collection and analysisData on extent and timing of surgery, quality of life outcomes, and surgical complications were extracted and study quality assessed.ResultsThree randomized controlled trials comparing primary surgery to neoadjuvant chemotherapy had heterogeneous quality of life outcomes with no difference between arms, although there was a clinical improvement in global quality of life scores in both arms at 6 months compared with baseline. Data from two observational studies showed no meaningful difference in quality of life scores between patients undergoing standard or extensive surgery at 6 months.ConclusionsThere was no clinically important difference in the quality of life of patients undergoing either primary debulking surgery or neoadjuvant chemotherapy. There is insufficient evidence on quality of life outcomes of patients undergoing extensive or ultra-radical surgery compared with those undergoing less extensive surgery. Quality of life outcomes matter to patients, but there is little evidence to inform patient choice regarding the extent of surgery.

Sentinel Lymph Node Procedure in Colon Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data

2020 ◽  
Author(s):  
Marjolein Ankersmit ◽  
Martijn W. Heymans ◽  
Otto Hoekstra ◽  
Stijn L. Vlek ◽  
Linda J. Schoonmade ◽  
...  
Keyword(s):  
Systematic Review ◽  
Colon Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Patient Data ◽  
Sentinel Lymph Node Procedure

scholarly journals Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis

2021 ◽  
Author(s):  
Chiel F. Ebbelaar ◽  
Anne M. L. Jansen ◽  
Lourens T. Bloem ◽  
Willeke A. M. Blokx
Keyword(s):  
Systematic Review ◽  
Sensitivity And Specificity ◽  
Copy Number ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Copy Number Variations ◽  
Patient Data ◽  
Melanocytic Lesions ◽  
Genome Wide ◽  
Malignant Lesions

AbstractCutaneous intermediate melanocytic neoplasms with ambiguous histopathological features are diagnostically challenging. Ancillary cytogenetic techniques to detect genome-wide copy number variations (CNVs) might provide a valuable tool to allow accurate classification as benign (nevus) or malignant (melanoma). However, the CNV cut-off value to distinguish intermediate lesions from melanoma is not well defined. We performed a systematic review and individual patient data meta-analysis to evaluate the use of CNVs to classify intermediate melanocytic lesions. A total of 31 studies and 431 individual lesions were included. The CNV number in intermediate lesions (median 1, interquartile range [IQR] 0–2) was significantly higher (p<0.001) compared to that in benign lesions (median 0, IQR 0–1) and lower (p<0.001) compared to that in malignant lesions (median 6, IQR 4–11). The CNV number displayed excellent ability to differentiate between intermediate and malignant lesions (0.90, 95% CI 0.86–0.94, p<0.001). Two CNV cut-off points demonstrated a sensitivity and specificity higher than 80%. A cut-off of ≥3 CNVs corresponded to 85% sensitivity and 84% specificity, and a cut-off of ≥4 CNVs corresponded to 81% sensitivity and 91% specificity, respectively. This individual patient data meta-analysis provides a comprehensive overview of CNVs in cutaneous intermediate melanocytic lesions, based on the largest pooled cohort of ambiguous melanocytic neoplasms to date. Our meta-analysis suggests that a cut-off of ≥3 CNVs might represent the optimal trade-off between sensitivity and specificity in clinical practice to differentiate intermediate lesions from melanoma.

Sign in / Sign up

Export Citation Format

Share Document